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After  many  years  of basic  research,  regenerative  medicine  (RM)  is  now  beginning  to  rep-
resent a valuable  tool  to cure  several  clinical  conditions  in  both  acute  injuries  and  chronic
diseases.  The  aim  of this  study  is  to  update  readers  on current  clinical  applications  of
some selected  organs  and pathologies  which  may  beneﬁt  from  RM.  An extensive  literature
research  was  performed  using  PubMed,  Google  and specialized  journals.  RM has achievedeywords:
egenerative medicine
issue engineering
rtiﬁcial organs
ell therapy
great  successes,  but there  are  still  several  challenges  to tackle  before  it could  be used  on
a daily basis  in  clinical  practice.  The  crucial  point  of this  revolution  is represented  by the
appropriate  and  valid  translation  from  bench  to bedside.
© 2016  Published  by  Elsevier  Ltd.  on  behalf  of  Saudi  Society  of  Microscopes.  This  is  an
open  access  article under  the  CC  BY-NC-ND  licenseranslational medicine.
. Introduction
Regenerative medicine (RM), from tissue engineering
TE) to cell therapy, offers valuable treatment options,
hich are rarely considered in daily clinical settings
1] Doctors, surgeons, clinicians and, in general, health-
are policies are not prone to substitute conventional
pproaches with innovative therapies without extended
nd thorough experiments. A major concern that limits the
preading of RM is related to different challenges to solve
eﬁnitively, e.g. live tissue handling and manufacturing [2].
In this article, the authors show how RM principles may
e applied, presenting some examples of artiﬁcial tissues
nd organs, which could be considered as a valid purpose
n daily clinical settings [3,4]. At present, RM is not the gold
tandard treatment for all the most common diseases. On
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the one hand, clinicians are not well informed about the
current applications; on the other hand, there are not many
studies conﬁrming safety, efﬁciency and effectiveness.
Therefore, we provide a brief reﬂection on the current
pre-clinical and clinical applications with their advantages
on traditional approaches and the issues that still need to be
solved before a massive spread. Further research is manda-
tory to offer the deﬁnitive cure for both acute injuries
and chronic diseases, but, ﬁrst of all, clinicians should be
informed of these possibilities and, later, form multidisci-
plinary team to adopt and deliver these new treatments.
2. Materials and methods
An exhaustive research of the latest clinical applica-
tions of RM was  conducted using appropriate index terms
(i.e. name of the organ AND tissue engineering or regen-
erative medicine AND clinical applications). These words
were typed in scientiﬁc databases and search engine, like
PubMed, Scopus, ScienceDirect and Google Scholar, to
roscopes. This is an open access article under the CC BY-NC-ND license
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obtain articles from specialized journals (e.g. The Lancet,
The Journal of Urology, Future Medicine Journals or the
open access scientiﬁc journal PLoS ONE). We  selected orig-
inal articles written in English and published within the
last two decades. Actually, most papers dated back to last
ﬁve years; the older ones are related to key steps in the
delivering of latest solutions.
Images were taken from PLoS ONE, as they could be
freely used and inserted into the present review [5].
3. Speciﬁc organs and tissues
Scientists are developing all kinds of tissues and organs
(from bladder to heart, from nerve to ovary etc); unfor-
tunately, just some of them have been already implanted
successfully in humans, while others are still in pre-clinical
phase, or have been developed recently [6]. We  selected
and reported below some artiﬁcial tissues and organs,
which have the potential to be implanted into humans on
routine clinical settings.
3.1. Bladder
Urinary bladder is a hollow organ, made up of two  func-
tional layers: an inner epithelium and an outer smooth
muscle layer. Therefore, its regeneration requires both
these layers in order to be successful. The gold standard
treatment for patients with pathologic bladders, which are
not responsive to any drugs, is to substitute or augment
the original bladder with bowel segments. However, the
gastrointestinal (GI) tissue is not adequate to stay in con-
tact with urine, as it is supposed to adsorb solutes, which
are normally accumulated and excreted. Therefore, it leads
to several complications: mucous production, urolithia-
sis, infection, perforation, metabolic disturbances and even
cancer [7]. These issues have generated sufﬁcient debate
and novel research strategies are demanded to avoid the
unwanted effects mentioned above. However, the storage
and voiding functions associated to a good compliance and
capacity of this organ are challenging to reproduce with TE.
Among several studies assessing bladder reconstruc-
tion with exogenous biomaterials, the Atala’s group
achieved excellent results in seven patients, aged 4-19
years, suffering from myelomeningocele [8]. These patients
needed augmentation cystoplasty, as they had severe
urinary incontinence because of their neuropathic blad-
ders (high-pressure or poorly compliant). Their bladders
were reconstructed using a collagen scaffold seeded with
patient’s own bladder cells either with or without omental
coverage, or a combined poly-glycolic acid (PGA)-collagen
scaffold covered with omentum. The three patients with
the composite collagen-PGA scaffold plus omental wrap
showed better results, with several improvements in terms
of preoperative values: bladder ﬁlling pressures decreased
56%, while the volume and the compliance increased 1.58-
fold and 2.79-fold, respectively. After a mean follow-up of
46 months, no metabolic consequences and renal stones
were noted and the mucous production and renal function
remained normal. At last, the engineered bladders biopsies
showed an adequate structural architecture and pheno-
type.and Ultrastructure 5 (2017) 1–8
Despite this excellent outcome, during the phase II of a
clinical study on eleven pediatric patients treated with the
PGA matrix seeded with autologous urothelial cells, there
was  no clinical or statistical improvement in bladder capac-
ity and compliance after a mean follow-up of 36 months.
Adverse events, such as bladder rupture (n=3) and bowel
obstruction (n=3), occurred in most of the patients and
needed to be treated through other surgeries [9]. The fail-
ure of this clinical study could be explained considering the
disease condition of the bladder which offered poor status
cells to seed onto scaffolds. In this way, it was  demon-
strated that the use of artiﬁcial urinary bladder is still far
from replacing the classic use of GI tissue for augmentation
cystoplasty.
Another solution, which was ﬁrst reported in rats after
partial cystectomy, is the use of bladder acellular matrix
(BAM), prepared by removing mechanically and chemi-
cally cellular components from bladder tissue [10]. Despite
many years of intense research, BAM alone had never been
able to achieve full bladder regeneration, as muscle lay-
ers developed incompletely [11]. Therefore, BAM is being
associated with stem cells to improve tissue regeneration
(Figure 1) [12].
Current available biomaterials for bladder TE are classi-
ﬁed in biological and synthetic ones. In addition to acellular
matrixes, other examples of biological scaffolds used for
treating the bladder are primarily made of collagen and
alginate; synthetic polymers include poly L-lactide (PLLA),
PGA and silk derivatives instead [13]. The advantages of
BAM and biological materials are related to good bio-
compatibility and biodegradability, while the processing
of synthetic materials allows to obtain scaffolds with
more reproducible and predictable physical behavior [14].
Although bladder TE is a promising alternative to tradi-
tional approaches, no strong beneﬁts emerged comparing
several biomaterials introduced in experimental stud-
ies [9,11,13]. Along with the deﬁnition of an adequate
biomaterial and scaffold, bladder TE has still many chal-
lenges to solve, such as the appropriate choice of animal
models; each animal model presents, indeed, its own
speciﬁcity [15]. For example, the composition of rabbits
urine conducted to the formation of bladder stones when
the animal is subjected to exogenous bladder material
implants [16]. Moreover, larger animals have a similar
anatomy to human body than rats or rabbits and this
help in being as close as possible to human situation
in clinical evaluation [17]. Another issue of the studies
reported in literature is the absence of a long follow-
up characterized by the comparison with a control group
treated with the gold standard treatment (GI tissues)
[18]. All these parameters need to be taken into account
and they are fundamental to ﬁnd the optimal procedures
for bladder regeneration before considering the clinical
application.
Besides the importance of preclinical study standardiza-
tion, greater interest is being reserved to obtain adequate
stem cells for urological tissue-engineered organs. In
this respect, Bharadwaj et al. [19] derived stem cells
from excreted urine and differentiated them into bladder
urothelial and smooth muscle phenotypes, demonstrating
a potential future perspective for urological care.
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Fig. 1. Images of BAM seeded with MSCs from human umbilicus taken by Scanning Electron Microscope (SEM). A At 5 days the cells migrate and proliferate
inside  BAM (magniﬁcation x2400). B At 10 days MSCs from human umbilicus ﬁll in the surface of BAM (magniﬁcation x1200).
Source: Yuan H, Zhuang Y, Xiong J, Zhi W,  Liu L, Wei  Q, Han P. Human umbilical mesenchymal stem cells-seeded bladder acellular matrix grafts for
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.2. Blood Vessels
Blood vessels are a striking example of application of
M strategies for engineering tubular organs. Since tissue-
ngineered vessels could be useful for common and life-
hreatening vascular lesions, research has been advanced
reatly [20,21].
A traditional TE approach is the construction of func-
ional living vascular grafts outside the body by using 3
lements: cells, scaffolds and bioreactors. Among all the
rgans, artiﬁcial blood vessels are the ones that are sig-
iﬁcantly developed by means of bioreactors: devices or
ystems able to reproduce biochemical/biophysical stimuli
s in a physiological conditions. Computer-controlled pul-
atile bioreactors seem to be superior then the old ones
s they could permit the adjustment over a range of pres-
ure and pulse rates, thus making great improvements in
ascular TE [22].
As an alternative to autologous grafts, also xenogeneic
r synthetic materials had largely been used, but, besides
acking of growth potential (key feature with pediatric
atients), they were related to an increased risk of stenosis,
nfection and thromboembolization [23–25].
Therefore, the right strategy proved to be the use of
iodegradable scaffolds seeded with patient’s own cells.
n this way, the autograft does not provoke immune
esponses and it degrades itself, leaving new tissue instead
f a foreign body. This technology had been tried not
nly in laboratory or in animal models, but even in
linical setting. Indeed, a tubular biodegradable scaffold,
reated with polycaprolactone-polylactic acid (PCL-PLA)
opolymer, reinforced with woven PGA and seeded with
ndothelial cells, was implanted to substitute a stenosed
ulmonary artery, repaired previously [26]. The cells were
btained from patient’s stem cells through a blood sam-
le. The tissue-engineered vascular autograft (TEVA) was
ater placed in a bioreactor system to acclimatize it to the):e80959. doi: 10.1371/journal.pone.0080959. eCollection 2013.
conditions of the body until implantation. Neither occlu-
sion nor aneurism of TEVA was observed in the recipient
7 months after implantation. Subsequently to Shin’oka’s
successful approach, 25 extracardiac cavopulmonary con-
nections with TEVA as a conduit were performed on
pediatric patients with mean age of 5.5 years [27].
Long-term follow-up at 4 years after implantation demon-
strated no instances of graft-related mortality, no cases of
aneurysm formation, graft rupture nor calciﬁcation. Only
two death were reported from late cardiac failure. This
ﬁrst human clinical trial conﬁrmed the efﬁciency of TEVA
and the absence of adverse events, such as graft rupture or
aneurismal change.
Even for tissue-engineered small diameter vessels (<
6 mm),  their development had been complicated by either
occlusion or thrombosis of the current strategies for long
time [28]. However, Kurobe et al. recently succeeded in
the construction and implantation in mice of a tissue engi-
neered vascular graft (TEVG) for small diameter arteries as
shown in Figure 2 [29].
Despite the promising clinical results with large
diameter engineered vessels, there are still some sig-
niﬁcant problems to solve, from the choice of material,
geometry and scaffold composition, which should be stan-
dardized, to the deﬁnition of an accurate process of
sterilization, preservation and transport of engineered
grafts.
Recently, the attention shifted towards scaffold-free
blood vessels realized by the bioprinting technology.
[30,31]. The letter uses a computer-controlled printing
device to deposit cell aggregates, cells and biomaterials or
cells encapsulated in hydrogels into deﬁned 3D geometries.
In this case, blood vessels with different diameters and cell
patterns were printed using spherical and cylindrical mul-
ticellular systems as bioink. Since the fabrication method
resulted accurate, reliable and scalable, further studies are
now required to take advantage of bioprinting beneﬁts to
4 F. Colombo et al. / Journal of Microscopy 
Fig. 2. Comparison between TEVG implantation to sham group. A TEVG
was  made of biodegradable electrospun polylactic acid (PLA) nanoﬁbers
(length=3mm; inner luminal diameter 500-600 m).  B implantation of
TEVG. The image shows inferior vena cava (IVC) and aorta (Ao).
C  Survival rate at 24 hours after surgery. < 10% of mice implanted with
TEVG died within 24 hours after TEVG implantation because of bleeding or
thrombosis. D Kaplan-Meier survival curve considering the 12 months of
experiment. No signiﬁcant statistical difference was  highlighted between
the two groups.
Source: Kurobe H, Maxﬁeld MW,  Tara S, Rocco KA, Bagi PS, Yi T, et al. (2015)
Development of Small Diameter Nanoﬁber Tissue Engineered Arterial
Grafts. PLoS ONE 10(4): e0120328. doi: 10.1371/journal.pone.0120328.
obtain reproducible implantable blood vessels in the near
future.
3.3. Skin
The skin is probably the best well-known engineered
organ and the daily clinical application of artiﬁcial skin is
not far at all. The clinical gold standard in full-thickness
injuries treatment is an autologous split-thickness graft,
which consists in the surgical removal and subsequent
stretching of epidermis and superﬁcial dermis from an
undamaged skin site of the patient; the autograft is thus
applied on the full-thickness wound or burn. However, in
case of extensive injuries, donor sites for autografts har-
vesting are not available. Allografts could be an additional
option, but they still suffer the need of immunosup-
pressive therapies. To overcome these inconvenient, many
research groups worldwide focused their attention on cre-
ating bioengineered skin substituted [32–34]. Some of the
commercially available dermo-biopolymer composites for
clinical applications are listed in Table 1 [35–41].
In addition to the current commercial skin substitutes,
different approaches has been developed to meet theand Ultrastructure 5 (2017) 1–8
demand of skin replacement. Among the most innovative
solutions, bioprinting is emerging as a potential tool for
skin TE applications. A printer designed to print skin cells
onto burn wounds had recently been built and tested at
the Wake Forest Institute for Regenerative Medicine (WFIRM)
[42]. Before printing, a scanner is used to determine wound
size and depth to calibrate the use of the ink, which, actu-
ally, includes different kinds of skin cells, collected from
a skin patch one-tenth the size of the burn. The same
research team has recently worked on the possibility to
use the amniotic ﬂuid-derived stem cells (AFSCs) to wound
treatment in a mouse model of skin regeneration [43].
After two-week observation, the AFSCs deposited in a colla-
gen/ﬁbrin gels accelerated closure and re-epithelialization
of full-thickness wounds in mice faster than gel-only
controls and were as effective as bone marrow-derived
mesenchymal stem cells (MSCs) treatments. Additionally,
histological examinations showed that AFS cells induced
stronger angiogenesis and blood vessel maturation com-
pared with the other two  groups. In conclusion, together
with commercial skin substitutes, bioprinting approach
will become an optimal treatment for burns and skin
wounds without requiring a secondary surgical site (as in
case of gold standard treatment) and without provoking
the patient’s immune response by using AFSCs.
3.4. Trachea
The success of a tissue-engineered trachea is deter-
mined only by its ability to conduct air lifelong, becoming
a sustainable biological conduit. Many attempts had been
tried to create an artiﬁcial trachea, but none showed supe-
rior.
On March 2010, at Great Ormond Street Hospital, in
London, a stem-cell based tissue-engineered trachea was
implanted in a 12-year-old child, born with congenital
long segment tracheal stenosis and pulmonary sling [44].
After a brief stimulation by granulocyte colony stimulat-
ing factor (G-CSF), bone marrow mesenchymal stem cells
(BMSCs) were obtained preoperatively and seeded onto
a scaffold with patches of autologous epithelium. Human
recombinant erythropoietin (EPO) was  applied topically to
stimulate angiogenesis, along with Transforming growth
factor beta (TGF-)  to support chondrogenesis. The graft re-
vascularized within 1 week after implantation. Epithelium
restoration became evident after 1 year, while the graft did
not have biomechanical strength focally until 18 months,
without requiring any medical interventions. Moreover, 18
months after surgery, he performed a chest CT scan and
ventilation-perfusion scan, which resulted normal. At 2
years follow-up, he had a functional airway and returned
to school, after growing 11 cm in height.
This study represents an evolution in the development
of tissue-engineered tracheas, representing the foundation
for future clinical applications.
3.5. VisionThe eye presents some advantages that makes it as an
optimal candidate for RM applications; in fact, it is easy to
access in order to perform pre-treatment assessments and
F. Colombo et al. / Journal of Microscopy and Ultrastructure 5 (2017) 1–8 5
Table  1
Some of the commercially available skin substitutes that have been successfully used in clinical practice.
Brand name/manufacturer Scaffold material Cells References
Dermagraft®
Advanced Biohealing, Westport,
CT, USA
PGA and PLA ﬁbers and
silicon ﬁlm
Fibroblasts Hart et al. [35]
Apligraf®
Organogenesis Inc., Canton,
Massachusetts, CA, USA
Bovine collagen Keratinocytes
and ﬁbroblasts
Falanga et al. [36]
OrCel®
Ortec International, Inc.,
New York, NY, USA
Bovine collagen sponge Keratinocytes
and ﬁbroblasts
Still et al. [37]
TissueTech Autograft System
(Laserskin®  and Hyalograft 3D®)
Fidia Advanced Biopolymers,
Abano Terme, Italy
Hyaluronic Acid Keratinocytes
and ﬁbroblasts
Caravaggi et al.[38]
Uccioli et al. [39]
Matriderm®
Dr. Suwelack Skin & Health Care,
Billerbeck, Germany
Acellular dermal
substitute
Keratinocytes
and ﬁbroblasts
(Figure 3) -Micheal et al. [40]
Min  et al. [41]
Fig. 3. Tissue engineered skin construct inserted into the mouse wound after the implantation (left) and on the 11th day (right), when the wound fully
healed.
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ollect cells, it can be simply observed and evaluated during
ollow-up and it is an immune-privileged organ. However,
he eye is composed by many different tissues, whose arti-
cial reconstructions are at a different stage of research
45].
Among all tissues, cornea is at the highest research
omain. Corneal scarring from trauma and inﬂammation
isrupts vision for millions worldwide, but corneal trans-
lantation, the primary therapy for corneal blindness, is
navailable to many affected individuals.
As an alternative to cadaveric corneas transplantation,
ransparent thin gelatin gel (TGG) scaffolds, functionalized
ith heparin, were fabricated to support transfer of cul-
ured human corneal endothelial cells (HCECs). Through a
mall incision in the cornea, the scaffold was implanted in
abbits’eye and gradually integrated with the surrounding
issue [46].Cellular therapy seems to offer a valid alternative as
ell. Stem cells from different sources had been isolated,
xpended in vitro, differentiated and proved to function aseimers K. Tissue engineered skin substitutes created by laser-assisted
 One. 2013;8(3):e57741. doi: 10.1371/journal.pone.0057741. Epub 2013
corneal cells in vivo. In Figure 4, the results associated to
the treatment of corneas burned by alkali and later seeded
with MSCs in rats are shown [47]. Moreover, Du et al. col-
lected human stem cells and transplanted them into mice
with genetically cloudy corneas, which, eventually, became
transparent [48].
In addition to these pre-clinical treatments, Holoclar®,
a stem cell-based medical product for the repair of the
outer layer of cornea damaged by chemical or physical
injuries, has recently been approved by European Com-
mission. The therapy is based on the biopsy of a tiny
portion (min 1-2 mm2) of the undamaged limbus and its
growth in laboratory using speciﬁc techniques. The limbus
is located between the sclera, the white part of the eye,
and the cornea, the front part of the eye, and it is rich in
stem cells able to heal the damaged cornea. Through this
system, a novel sheet of cornea can be developed and trans-
planted back onto the eye. The combination of Holoclar®
and corneal transplants can restore a normal cornea for
previously incurable, deep corneal burns.
6 F. Colombo et al. / Journal of Microscopy and Ultrastructure 5 (2017) 1–8
Fig. 4. MSCs improve corneal wound healing. A–D Fluorescein-stained corneas of the control group show reduced recovery in reference to group treated
with  MSCs. E Percentage analysis of ﬂuorescein-stained corneas highlights a signiﬁcant statistical difference between the two groups: MSC group stained
on of co
 D. Role
842. Epuin  a very lower manner than the control group, conﬁrming the accelerati
Source: Yao L, Li ZR, Su WR,  Li YP, Lin ML, Zhang WX,  Liu Y, Wan  Q, Liang
alkali  burn. PLoS One. 2012;7(2):e30842. doi: 10.1371/journal.pone.0030
Together with cornea, also retina is involved in dif-
ferent eyes disease such as retinitis pigmentosa, diabetic
retinopathy and age-related macular degeneration (AMD).
The latter is considered as the leading cause of vision
loss among older people. AMD  is multifactorial disease
which interests retinal pigment epithelium degeneration
and it ends with the damage of the retina central portion
that, eventually, conducts to the patient’s vision loss. The
traditional therapy consists of drugs able to stop neovascu-
larization, but not able to repair the precedent damage. For
this reason, recent progress have been made in the ﬁeld
of cell therapies for RPE treatment, including the use of
induced pluripotent stem cells (iPSCs) and embryonic stem
cells (ESCs) [51].
In particular, at the end of 2014 in Japan, at the RIKEN
Center for Developmental Biology, a 70-year-old woman,
suffering from AMD, was treated by using iPSCs, taken
by hers and transplanted as a 1.3-3 mm RPE mono-layer
without the use of synthetic scaffolds or matrices [52]. No
complications appeared with the transplant surgery and
a one-year monitoring period was set to evaluate the ini-
tial results of the research. The technology described above
represents a real breakthrough and is able to give faith to
all patients suffering from AMD.
Recently, an American stem cell-based company
reported successful completion of two phase I/II clinicalrneal wound healing.
 of mesenchymal stem cells on cornea wound healing induced by acute
b 2012 Feb 17.
trials for human ES-derived RPE cell suspension trans-
planted in 18 patients suffering from Stargardt’s disease or
with AMD. No major adverse events and immune responses
were noted in any patient over a mean 22 months follow-up
[53].
In conclusion, stem cell-based therapy could represent
an effective solution for the cure of retinal degenerative
disease.
4. Conclusions
Every 30 seconds a patient dies from diseases which
could be treated with tissue replacement [54]. A tissue
engineering and regenerative medicine (TERM) approach
could probably offer the deﬁnitive solution for children
with congenital malformations, young soldiers disﬁgured
in war and old people suffering from chronic invali-
dating diseases, which are burdening more and more
heavily on world’s national economies [55]. As described
before in detail, current researches are supporting valu-
able directions to improve clinical applications of TE
[12,26,28,40,41,49,50].Researchers are asked to direct their efforts towards
the translation of the many different laboratory ﬁndings
into modern and viable therapies: a close collabora-
tion between clinicians and other scientists (bioengineers,
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aterials engineers, biologists) is mandatory to translate
asic scientiﬁc discoveries in TERM therapies to help their
pread. However, efﬁcacy and efﬁciency of these new solu-
ions must be carefully evaluated before clinical trials.
peciﬁcally, pre-clinical studies ought to be constructed
ccording to the following principles:[18]
 Enrollment of large samples;
 Use of tissue/organ constructs which present similar
dimensions as human ones;
 Appropriate choice of animals models which should not
report over- or under- estimations;
 Selection of pertinent bioreactors (specially for vessels) to
improve the construction of the artiﬁcial organ by means
of adequate stimuli;
 Use of diseased tissues and/or dysfunctional animal
organs in view of clinical applications;
 Long follow-up;
 Comparisons with the gold standard treatment.
In order to stimulate reader’s research interests, the
uthors would like to highlight major challenges which
eed to be solved in future:
 Vascularization and innervation of artiﬁcial constructs;
 Engineering organs with different cell types;
 Construction of validated bioreactors to avoid animal
testing;
 Conducting appropriate pre-clinical and clinical trials fol-
lowing the principles indicated above in order to make
TERM approach the gold standard treatment for every
diseases.
When all these issues are completely overcome, TERM
pproach will become superior to existing clinical thera-
ies.
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eferences
[1] Sampogna G, Guraya SY, Forgione A. Regenerative medicine: His-
torical roots and potential strategies in modern medicine. JMAU
September 2015;Volume 3(Issue 3):101–7.
[2] Gardner J, Webster A. The social management of biomedical nov-
elty: Facilitating translation in regenerative medicine. Social Science
&  Medicine 2016;156:90–7.
[3] Alberti C. Tissue engineering technologies: just a quick note about
transplantation of bioengineered donor trachea and augmenta-
tion  cystoplasty by de novo engineered bladder tissue. G Chir
2009;30:514–9.
[4] Langer R, Vacanti J. Advances in tissue engineering. J Pediatr Surg
2016;51:8–12.
[5] http://www.plosone.org/.
[6] www.  clinicaltrials.gov consulted for “Regenerative Medicine” trials
on  February 2016.
[7] Nieuwenhuijzen JA, De Vries RR, Bex A, Van der Poel HG, Meinhardt
W,  Antonini N. Urinary diversion after cystectomy: the association of
clinical factors, complications and functional results of four different
diversion. Eur Urol 2008;53:834–42.
[8] Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered
autologous bladders for patients needing cystoplasty. Lancet
2006;367(9518):1241–6.
[
[and Ultrastructure 5 (2017) 1–8 7
[9] Joseph DB, Borer JG, De Filippo RE, Hodges SJ, McLorie GA. Autologous
cell  seeded biodegradable scaffold for augmentation cystoplasty:
phase II study in children and adolescents with spina biﬁda. J Urol
2014;191(5):1389–95.
10] Sutherland RS, Baskin LS, Hayward SW,  Cunha GR. Regeneration of
bladder urothelium, smooth muscle, blood vessels and nerves into
an acellular tissue matrix. J Urol 1996;156(2):571–7.
11] Jayo MJ,  Jain D, Ludlow JW,  Payne R, Wagner B, McLoire G, et al. Long-
term durability, tissue regeneration and neo-organ growth during
skeletal maturation with a neo-bladder augmentation construct.
Regen Med  2008;3(5):671–82.
12] Yuan H, Zhuang Y, Xiong J, Zhi W,  Liu L, Wei  Q, et al. Human umbil-
ical mesenchymal stem cells-seeded bladder acellular matrix grafts
for reconstruction of bladder defects in a canine model. PLoS ONE
2013;8(11):e80959.
13] Lam Van Ba O, Aharony S, Loutochin O, Corcos J. Bladder tissue
engineering: A literature review. Advanced Drug Delivery Reviews
2015;82-83:31–7.
14] Chapple CR, Osman N, Mangera A, Hillary C, Roman S, Bullock A, et al.
Application of tissue engineering to pelvic organ prolapse and stress
urinary incontinence. LUTS 2015;7:63–70.
15] Sloff M,  De Vries R, Geutjes P, IntHout J, Ritskes-Hoitinga M,  Ooster-
wijk E. Tissue engineering in animal models for urinary diversion: a
systematic review. PLoS ONE 2014;9(6):e98734.
16] Nuininga JE, van Moerkerk H, Hanssen A, Hulsbergen CA, Oosterwijk-
Wakka J, Oosterwijk E, et al. A rabbit model to tissue engineer the
bladder. Biomaterials 2004;25:1657–61.
17] Roth CC, Mondalek FG, Kibar Y, Ashley RA, Bell CH, Califano JA,
et al. Bladder regeneration in a canine model using hyaluronic acid-
poly(lactic-co-glycolicacid) nanoparticle modiﬁed porcine small
intestinal submucosa. BJU 2011;108:148–55.
18] Sloff M, Simaioforidis V, De Vries R, Oosterwijk E, Feitz W.  Tissue
Engineering of the Bladder - Reality or Myth? A Systematic Review.
J  Urol 2014;192(4):1035–42.
19] Bharadwaj S1, Liu G, Shi Y, Wu R, Yang B, He T, et al. Multipoten-
tial  differentiation of human urine-derived stem cells:potential for
therapeutic applications in urology. Stem Cells 2013;31(9):1840–56.
20] Li S, Sengupta D, Chien S. Vascular tissue engineering: from in vitro
to  in situ. WIREs Syst Biol Med  2014;6:61–76.
21] Zou T, Fan J, Fartash A, Liu H, Fan Y. Cell-based strategies for vascular
regeneration. J Biomed Mater Res A 2016;00A(00):1–18.
22] Song L, Zhou Q, Duan P, Guo P, Li D, Xu Y, et al. Successful development
of small diameter tissue-engineering vascular vessels by our novel
integrally designed pulsatile perfusion-based bioreactor. PLoS ONE
2014;7(8):e42569.
23] Deutsch M,  Meinhart J, Fischlein T, Preiss P, Zilla P. Clinical autolo-
gous in vitro endothelialization of infrainguinal ePTFE grafts in 100
patients: a 9-Year experience. Surgery 1999;126:847–55.
24] Gabbieri D, Dohmen PM,  Koch C, Lembcke A, Rutsch W,  Konertz
W.  Aortocoronary endothelial cell-seeded polytetraﬂuoroethylene
graft: 9-Year patency. Ann Thorac Surg 2007;83:1166–8.
25] Matsumura G, Miyagawa-Tomita S, Shin’oka T, Ikada Y, Kurosawa
H. First evidence that bone marrow cells contribute to the con-
struction of tissue-engineered vascular autografts in vivo. Circulation
2003;108:1729–34.
26] Shin’oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered
pulmonary artery. N. Engl. J. Med 2001;344:532–3.
27] Kurobe H, Maxﬁeld MW,  Breuer CK, Shin’oka T. Concise review:
tissue-engineered vascular grafts for cardiac surgery: past, present,
and future. Stem Cells Transl. Med  2012;1:566–71.
28] Peck M,  Gebhart D, Dusserre N, McAllister TN, L’Heureux N. The evo-
lution of vascular tissue engineering and current state of the art. Cells,
tissues, organs 2012;195(1–2):144–58.
29] Kurobe H, Maxﬁeld MW,  Tara S, Rocco KA, Bagi PS, Yi T, et al. Devel-
opment of small diameter nanoﬁber tissue engineered arterial grafts.
PLoS ONE 2015, http://dx.doi.org/10.1371/journal.pone.0120 328.
30]  Norotte C, Marga F, Niklason L, Forgacs G. Scaffold-Free Vas-
cular Tissue Engineering Using Bioprinting. Biomaterials
2009;30(30):5910–7.
31] Shaﬁee A, Atala A. Printing Technologies for Medical Applications.
Trends in Molecular Medicine 2016;22(3):254–65.
32] Shevchenko RV, James SL, James SE. A review of tissue-engineered
skin bio constructs available for skin reconstruction. J.R. Soc. Interface
2010;7:229–58.33] Halim AS, Khoo TL, Shah JM.  Biologic and synthetic skin substitutes:
An overview. Indian J Plast Surg 2010;43(Suppl S1):23–30.
34] Lepow BD, Downey M,  Yurgelon J, Klassen L, Armstrong DG.
Bioengineered tissues in wound healing. Expert Rev Dermatol
2011;6(3):255–62.
roscopy 
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[8 F. Colombo et al. / Journal of Mic
35] Hart CE, Loewen-Rodriguez A, Lessem J. Dermagraft: Use in
the Treatment of Chronic Wounds. Advances in Wound Care
2012;1(3):138–41.
36] Falanga V, Sabolinski ML.  A bilayered living skin construct
(Apligraf®) accelerates complete closure of hard-to-heal venous
ulcers. Wound Repair Regen 1999;7:201–7.
37] Still J, Glat P, Silverstein P, Griswold J, Mozingo D. The use of a collagen
sponge/living cell composite material to treat donor sites in burn
patients. Burns 2003;29:837–41.
38] Caravaggi C, De Giglio R, Pritelli C, Sommaria M,  Della Noce S, Faglia
E,  et al. HYAFF 11–Based autologous dermal and epidermal grafts in
the treatment of non-infected diabetic plantar and dorsal foot ulcers.
Diabetes Care 2003;26(10):2853–9.
39] Uccioli L. A clinical investigation on the characteristics and outcomes
of treating chronic lower extremity wounds using the tissue tech
autograft system. Int. J. Low Extrem. Wounds 2003;2:140–51.
40] Michael S, Sorg H, Peck CT, Koch L, Deiwick A, Chichkov B, et al. Tis-
sue engineered skin substitutes created by laser-assisted bioprinting
form skin-like structures in the dorsal skin fold chamber in mice. PLoS
ONE 2013;8(3):e57741.
41] Min  JH, Yun IS, Lew DH, Roh TS, Lee WJ.  The use of Matriderm and
autologous skin graft in the treatment of full thickness skin defects.
Arch Plast Surg 2014;41(4):330–6.
42] Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat.
Biotechnol 2014;32(8):773–85.
43] Skardal A, Mack D, Kapetanovic E, Anthony Atala A, Jackson JD,
Yoo J, et al. Bioprinted Amniotic Fluid-Derived Stem Cells Accel-
erate Healing of Large Skin Wounds. Stem Cells Transl. Med 2012
Nov;1(11):792–802.
44] Elliott MJ,  De Coppi P, Speggiorin S, Roebuck D, Butler CR, Samuel
E, et al. Stem-cell-based, tissue engineered tracheal replacement
[
[and Ultrastructure 5 (2017) 1–8
in a child: a 2-year follow-up study. Lancet 2012;380(9846):
994–1000.
45] Elisseeff J, Madrid MG,  Lu Q, Chae JJ, Guo Q. Future Perspectives for
Regenerative Medicine in Ophthalmology. Middle East Afr. J. Oph-
thalmol 2013;20(1):38–45.
46] Niu G, Choi JS, Wang Z, Skardal A, Giegengack M,  Soker S.
Heparin-modiﬁed gelatin scaffolds for human corneal endothelial
cell transplantation. Biomaterials 2014;35(13):4005–14.
47] Yao L, Li ZR, Su WR,  Li YP, Lin ML,  Zhang WX,  et al. Role of Mesenchy-
mal  Stem Cells on Cornea Wound Healing Induced by Acute Alkali
Burn. PLoS ONE 2012;7(2):e30842.
48] Du Y, Carlson EC, Funderburgh ML,  Birk DE, Pearlman E, Guo N,
et  al. Stem Cell Therapy Restores Transparency to Defective Murine
Corneas. Stem Cells 2009;27(7):1635–42.
49] http://www.holostem.com/Consulted on December 2015.
50] http://www.esgct.eu/home/First%20stem%20cell%20therapy%20
recommended%20for%20approval%20in%20EU.pdf Consulted on
December 2015.
51] Song MJ,  Bharti K. Looking into the future: Using induced pluripo-
tent stem cells to build two and three dimensional ocular tissue
for  cell therapy and disease modeling. Brain Research 2015,
http://dx.doi.org/10.1016/j.brainres.2015.12.011.
52] http://www.cdb.riken.jp/en/news/2014/researches/0915 3047.html
Consulted on December 2015.
53] Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori
NZ, et al. Human embryonic stem cell-derived retinal pigment
epithelium in patients with age-related macular degeneration and
Stargardt’s macular dystrophy: follow-up of two open-label phase
1/2  studies. Lancet 2015;385:509–16.
54] Anthony, Atala. Growing new organs. TEDMED Event Jan 2010.
55] The 2012 OASDI Trustees Report. Table IV.B2.
